291 related articles for article (PubMed ID: 26059077)
1. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.
Afshar M; Evison F; James ND; Patel P
Urol Oncol; 2015 Aug; 33(8):338.e1-7. PubMed ID: 26059077
[TBL] [Abstract][Full Text] [Related]
2. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
3. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
[TBL] [Abstract][Full Text] [Related]
4. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
Heck MM; Thalgott M; Schmid SC; Oh WK; Gong Y; Wang L; Zhu J; Seitz AK; Porst D; Höppner M; Retz M; Gschwend JE; Nawroth R
Prostate; 2016 Sep; 76(13):1160-8. PubMed ID: 27198487
[TBL] [Abstract][Full Text] [Related]
5. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
6. The impact of time to metastasis on overall survival in patients with prostate cancer.
Frees S; Akamatsu S; Bidnur S; Khalaf D; Chavez-Munoz C; Struss W; Eigl BJ; Gleave M; Chi KN; So A
World J Urol; 2018 Jul; 36(7):1039-1046. PubMed ID: 29488095
[TBL] [Abstract][Full Text] [Related]
7. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden.
Aly M; Leval A; Schain F; Liwing J; Lawson J; Vágó E; Nordström T; Andersson TM; Sjöland E; Wang C; Eloranta S; Akre O
Scand J Urol; 2020 Apr; 54(2):115-121. PubMed ID: 32266854
[No Abstract] [Full Text] [Related]
8. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T
Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469
[TBL] [Abstract][Full Text] [Related]
9. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.
Nakabayashi M; Hayes J; Taplin ME; Lefebvre P; Lafeuille MH; Pomerantz M; Sweeney C; Duh MS; Kantoff PW
Cancer; 2013 Aug; 119(16):2990-8. PubMed ID: 23719969
[TBL] [Abstract][Full Text] [Related]
10. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
[TBL] [Abstract][Full Text] [Related]
11. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial.
Buelens S; Poelaert F; Dhondt B; Fonteyne V; De Visschere P; Ost P; Verbeke S; Villeirs G; De Man K; Rottey S; Decaestecker K; Lumen N
Urol Oncol; 2018 Apr; 36(4):158.e13-158.e20. PubMed ID: 29336978
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
[TBL] [Abstract][Full Text] [Related]
13. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials.
West TA; Kiely BE; Stockler MR
Eur J Cancer; 2014 Jul; 50(11):1916-24. PubMed ID: 24825113
[TBL] [Abstract][Full Text] [Related]
14. Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience.
Sciarra A; Gentile V; Cattarino S; Gentilucci A; Alfarone A; D'Eramo G; Salciccia S
Int J Urol; 2015 Jan; 22(1):98-103. PubMed ID: 25186970
[TBL] [Abstract][Full Text] [Related]
15. Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians.
Sureka SK; Maheshwari R; Agnihotri S; Mitash N; Ahmad S; Mandhani A
Indian J Med Res; 2016 May; 143(Supplement):S68-S73. PubMed ID: 27748280
[TBL] [Abstract][Full Text] [Related]
16. Assessment of a Clinical Trial-Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer.
Coquet J; Bievre N; Billaut V; Seneviratne M; Magnani CJ; Bozkurt S; Brooks JD; Hernandez-Boussard T
JAMA Netw Open; 2021 Jan; 4(1):e2031730. PubMed ID: 33481032
[TBL] [Abstract][Full Text] [Related]
17. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
Xie W; Stopsack KH; Drouin SJ; Fu H; Pomerantz MM; Mucci LA; Lee GM; Kantoff PW
Prostate; 2019 Jan; 79(1):73-80. PubMed ID: 30141208
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials.
Tunio M; Al Asiri M; Al Hadab A; Bayoumi Y
Drug Des Devel Ther; 2015; 9():5291-9. PubMed ID: 26451085
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.
Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
Urology; 2016 Oct; 96():171-176. PubMed ID: 27318265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]